[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA05004919A - Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina. - Google Patents

Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.

Info

Publication number
MXPA05004919A
MXPA05004919A MXPA05004919A MXPA05004919A MXPA05004919A MX PA05004919 A MXPA05004919 A MX PA05004919A MX PA05004919 A MXPA05004919 A MX PA05004919A MX PA05004919 A MXPA05004919 A MX PA05004919A MX PA05004919 A MXPA05004919 A MX PA05004919A
Authority
MX
Mexico
Prior art keywords
gemcitabine
cdk inhibitor
pharmaceutical composition
relates
cdk
Prior art date
Application number
MXPA05004919A
Other languages
English (en)
Inventor
Giannella-Borradori Athos
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0225875.4A external-priority patent/GB0225875D0/en
Priority claimed from GB0300294A external-priority patent/GB0300294D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of MXPA05004919A publication Critical patent/MXPA05004919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un primer aspecto de la presente invencion se refiere a una combinacion que comprende un inhibidor CDK y gemcitabina. Un segundo aspecto de la presente invencion se refiere a un producto farmaceutico que comprende un inhibidor CDK y gemcitabina en la forma de una preparacion combinada para uso en forma simultanea, en secuencias o por separado en terapia. Un tercer aspecto de la presente invencion, se refiere a un metodo para tratar un padecimiento proliferativo, en donde el metodo comprende administrar a un sujeto en forma simultanea, en secuencias o por separado un inhibidor CDK y gemcitabina.
MXPA05004919A 2002-11-06 2003-11-05 Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina. MXPA05004919A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0225875.4A GB0225875D0 (en) 2002-11-06 2002-11-06 Combination
GB0300294A GB0300294D0 (en) 2003-01-07 2003-01-07 Combination
PCT/GB2003/004759 WO2004041308A1 (en) 2002-11-06 2003-11-05 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine

Publications (1)

Publication Number Publication Date
MXPA05004919A true MXPA05004919A (es) 2005-08-18

Family

ID=32313985

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004919A MXPA05004919A (es) 2002-11-06 2003-11-05 Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.

Country Status (8)

Country Link
US (1) US20050267066A1 (es)
EP (1) EP1558289A1 (es)
JP (1) JP2006508184A (es)
AU (1) AU2003276453A1 (es)
BR (1) BR0316004A (es)
CA (1) CA2502979A1 (es)
MX (1) MXPA05004919A (es)
WO (1) WO2004041308A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
ES2282299T3 (es) 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
ES2392544T3 (es) * 2005-06-07 2012-12-11 Yale University Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
EP2061446A2 (en) * 2006-07-28 2009-05-27 University Court of the University of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
ATE538652T1 (de) * 2007-05-15 2012-01-15 Piramal Life Sciences Ltd Synergistische pharmazeutische kombination für die behandlung von krebs
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
ES2622559T3 (es) 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
JPWO2014010742A1 (ja) * 2012-07-13 2016-06-23 学校法人神戸学院 モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3019166B1 (en) 2013-07-12 2019-05-08 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
CN113559058A (zh) * 2021-07-30 2021-10-29 石家庄学院 吉西他滨氨基酸注射液

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
JP2004524277A (ja) * 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
AU2002228692A1 (en) * 2000-12-01 2002-06-11 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors
EP1351956A1 (en) * 2000-12-08 2003-10-15 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
JP2006508184A (ja) 2006-03-09
CA2502979A1 (en) 2004-05-21
WO2004041308A1 (en) 2004-05-21
US20050267066A1 (en) 2005-12-01
BR0316004A (pt) 2005-09-13
AU2003276453A1 (en) 2004-06-07
EP1558289A1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
HUP0401423A3 (en) Isoxazolidine, pyrazolidine and dihydro-pyrazole derivatives as inhibitors of dipeptidyl peptidase iv, their use and pharmaceutical compositions containing them
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
MXPA06000464A (es) Uso de biotina o un derivado de biotina para aclarar la piel y tratar manchas por envejecimiento.
GB0328180D0 (en) Combination
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
MXPA05004917A (es) Combinacion que comprende docetaxel y un inhibidor cdk.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
MXPA04009396A (es) Combinacion que comprende un inhibidor cdk y doxorubicina.
BR0316029A (pt) Combinação
WO2007054725A3 (en) Combination of a cdk-inhibitor and a hdac-inhibitor
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
IL166596A0 (en) Salt of morphine-6-glucoronide